Guillain–Barré syndrome

Autoimmunity Reviews

Volumn 16, Issue 1, 2017, Pages 96-101

  Esposito, Susanna ^a   Longo, Maria Roberta ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Acute inflammatory demyelinating polyneuropathy; Acute motor axonal neuropathy; Acute paralytic neuropathy; Guillain Barr syndrome

Indexed keywords

ACUTE INFLAMMATORY DEMYELINATING POLYNEUROPATHY; AXONAL INJURY; CLINICAL FEATURE; DISEASE SEVERITY; ENTEROVIRUS D; ENTEROVIRUS D68; ENTEROVIRUS INFECTION; GUILLAIN BARRE SYNDROME; HUMAN; NONHUMAN; PATHOGENESIS; REVIEW; ZIKA FEVER; ZIKA VIRUS; ANIMAL; DISEASE MANAGEMENT; GUILLAIN-BARRE SYNDROME; IMMUNOLOGY;

IMMUNOLOGIC FACTOR;

ANIMALS; DISEASE MANAGEMENT; GUILLAIN-BARRE SYNDROME; HUMANS; IMMUNOLOGIC FACTORS;

EID: 85006160436     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2016.09.022     Document Type: Review

References (68)

1. [1] Sejvar, J.J., Baughman, A.L., Wise, M., Morgan, O.W., Population incidence of Guillain–Barré syndrome: a systematic review and meta-analysis. Neuroepidemiology 36 (2011), 123–133.
2. [2] Ropper, A., The Guillain–Barré symptom complex. N Engl J Med 17 (1992), 1130–1136.
3. [3] Schessl, J., Luther, B., Kirschener, J., Mauff, G., Korinthenberg, R., Infections and vaccinations preceding childhood Guillain–Barré symptom complex: a prospective study. Eur J Pediatr 165 (2006), 605–612.
4. [4] Ho, T., Griffin, J., Guillain–Barré syndrome. Curr Opin Neurol 12 (1999), 389–394.
5. [5] Alter, M., The epidemiology of Guillain–Barré syndrome. Ann Neurol 27 (1990), S7–12.
6. [6] Willison, H.J., Jacobs, B.C., van Doorn, P.A., Guillain–Barré syndrome. Lancet 388 (2016), 717–727.
7. [7] Walgaard, C., Lingsma, H.F., Ruts, L., van Doorn, P.A., Steyerberg, E.W., Jacobs, B.C., Early recognition of poor prognosis in Guillain–Barré syndrome. Neurology 76 (2011), 968–975.
8. [8] Hughes, R.A., Wijdicks, E.F., Benson, E., Cornblath, D.R., Hahn, A.F., Meythaler, J.M., Sladky, J.T., Barohn, R.J., Stevens, J.C., Group, M.C., Supportive care for patients with Guillain–Barré syndrome. Arch Neurol 62 (2005), 1194–1198.
9. [9] Winner, S.J., Evans, J.C., Age-specific incidence of Guillain–Barré syndrome in Oxfordshire. Q J Med 77 (1990), 1297–1304.
10. [10] Halls, J., Bredkjaer, C., Friis, M.L., Guillain–Barré syndrome; diagnostic criteria, epidemiology, clinical course and prognosis. Acta Neurol Scand 78 (1998), 118–122.
11. [11] Beth, A.R., Guillain–Barré syndrome. Pediatr Rev 33 (2012), 164–170.
12. [12] Hughes, R.A., Cornblath, D.R., Guillain–Barré syndrome. Lancet 366 (2005), 1653–1666.
13. [13] van Koningsveld, R., van Doorn, P.A., Schmitz, P.I., Ang, C.W., van der Mechè, F.G., Mild forms of Guillain–Barré syndrome in an epidemiologic survey in The Netherlands. Neurology 54 (2000), 620–625.
14. [14] Bogliun, G., Beghi, E., Incidence and clinical features of acute inflammatory polyradiculoneuropathy in Lombardy, Italy. Acta Neurol Scand 110 (2004), 100–106.
15. [15] Jasti, A.K., Selmi, C., Sarmiento-Monroy, J.C., Vega, D.A., Anaya, J.M., Gershwin, M.E., Guillain–Barré syndrome: causes, immunopathogenic mechanisms and treatment. Expert Rev Clin Immunol, 2016, 1–15 [Epub Jun 21].
16. [16] Loshaj-Shala, A., Regazzoni, L., Daci, A., Orioli, M., Brezovska, K., Panovska, A.P., Beretta, G., Suturkova, L., Guillain Barré syndrome (GBS): new insights in the molecular mimicry between C. jejuni and human peripheral nerve (HPN) proteins. J Neuroimmunol 289 (2015), 168–176.
17. [17] Orlikowski, D., Porcher, R., Sivadon-Tardy, V., Quincampoix, J.C., Raphaël, J.C., Durand, M.C., Sharshar, T., Roussi, J., Caudie, C., Annane, D., Rozenberg, F., Leruez-Ville, M., Gaillard, J.L., Gault, E., Guillain–Barré syndrome following primary cytomegalovirus infection: a prospective cohort study. Clin Infect Dis 52 (2011), 837–844.
18. [18] Tselis, A.C., Epstein–Barr virus infections of the nervous system. Handb Clin Neurol 123 (2014), 285–305.
19. [19] Hawken, S., Kwong, J.C., Deeks, S.L., Crowcroft, N.S., McGeer, A.J., Ducharme, R., Campitelli, M.A., Coyle, D., Wilson, K., Simulation study of the effect of influenza and influenza vaccination on risk of acquiring Guillain–Barré syndrome. Emerg Infect Dis 21 (2015), 224–231.
20. [20] Ghaderi, S., Gunnes, N., Bakken, I.J., Magnus, P., Trogstad, L., Håberg, S.E., Risk of Guillain–Barré syndrome after exposure to pandemic influenza a(H1N1)pdm09 vaccination or infection: a Norwegian population-based cohort study. Eur J Epidemiol 31 (2016), 67–72.
21. [21] Meyer Sauteur, P.M., Huizinga, R., Tio-Gillen, A.P., Roodbol, J., Hoogenboezem, T., Jacobs, E., van Rijn, M., van der Eijk, A.A., Vink, C., de Wit, M.Y., van Rossum, A.M., Jacobs, B.C., Mycoplasma pneumoniae triggering the Guillain–Barré syndrome: a case–control study. Ann Neurol, 2016 [Epub Aug 4].
22. [22] Williams, C.J., Thomas, R.H., Pickersgill, T.P., Lyons, M., Lowe, G., Stiff, R.E., Moore, C., Jones, R., Howe, R., Brunt, H., Ashman, A., Mason, B.W., Cluster of atypical adult Guillain–Barré syndrome temporally associated with neurological illness due to EV-D68 in children, South Wales, United Kingdom, October 2015 to January 2016. Euro Surveill, 2016, 2016, 21.
23. [23] Cao-Lormeau, V.M., Blake, A., Mons, S., Lastère, S., Roche, C., Vanhomwegen, J., Dub, T., Baudouin, L., Teissier, A., Larre, P., Vial, A.L., Decam, C., Choumet, V., Halstead, S.K., Willison, H.J., Musset, L., Manuguerra, J.C., Despres, P., Fournier, E., Mallet, H.P., Musso, D., Fontanet, A., Neil, J., Ghawché, F., Guillain–Barré syndrome outbreak associated with Zika virus infection in French Polynesia: a case–control study. Lancet 387 (2016), 1531–1539.
24. [24] Broutet, N., Krauer, F., Riesen, M., Khalakdina, A., Almiron, M., Aldighieri, S., Espinal, M., Low, N., Dye, C., Zika virus as a cause of neurologic disorders. N Engl J Med 374 (2016), 1506–1509.
25. [25] Lucchese, G., Kanduc, D., Zika virus and autoimmunity: from microcephaly to Guillain–Barré syndrome, and beyond. Autoimmun Rev 15 (2016), 801–808.
26. [26] Lucchese, G., Kanduc, D., Reply concerning the article “Zika virus and autoimmunity: from microcephaly to Guillain–Barré syndrome, and beyond”. Autoimmun Rev, 15, 2016, 854.
27. [27] Gadre, G., Satishchandra, P., Mahadevan, A., Suja, M.S., Madhusudana, S.N., Sundaram, C., Shankar, S.K., Rabies viral encephalitis: clinical determinants in diagnosis with special reference to paralytic form. J Neurol Neurosurg Psychiatry 81 (2010), 812–820.
28. [28] Martín Arias, L.H., Sanz, R., Sáinz, M., Treceño, C., Carvajal, A., Guillain–Barré syndrome and influenza vaccines: a meta-analysis. Vaccine 33 (2015), 3773–3778.
29. [29] Bardenheier, B.H., Duderstadt, S.K., Engler, R.J., McNeil, M.M., Adverse events following pandemic influenza a (H1N1) 2009 monovalent and seasonal influenza vaccinations during the 2009–2010 season in the active component U.S. military and civilians aged 17–44 years reported to the Vaccine Adverse Event Reporting System. Vaccine 34 (2016), 4406–4414.
30. [30] Haber, P., Sejvar, J., Mikaeloff, Y., DeStefano, F., Vaccines and Guillain–Barré syndrome. Drug Saf 32 (2009), 309–323.
31. [31] Soliven, B., Animal models of autoimmune neuropathy. ILAR J 54 (2014), 282–290.
32. [32] Sudo, M., Miyaji, K., Späth, P.J., Morita-Matsumoto, K., Yamaguchi, Y., Yuki, N., Polyclonal IgM and IgA block in vitro complement deposition mediated by anti-ganglioside antibodies in autoimmune neuropathies. Int Immunopharmacol. 40 (2016), 11–15.
33. [33] Kuwabara, S., Guillain–Barré syndrome. Epidemiology, pathophysiology and management. Drugs 64 (2004), 597–610.
34. [34] DiCapua, D.B., Lakraj, A.A., Nowak, R.J., Robeson, K., Goldstein, J., Patwa, H., Relationship between cerebrospinal fluid protein levels and electrophysiologic abnormalities in Guillain–Barré syndrome. J Clin Neuromuscul Dis 17 (2015), 47–51.
35. [35] Moise, L., Beseme, S., Tassone, R., Liu, R., Kibria, F., Terry, F., Martin, W., De Groot, A.S., T cell epitope redundancy: cross-conservation of the TCR face between pathogens and self and its implications for vaccines and autoimmunity. Expert Rev Vaccines 15 (2016), 607–617.
36. [36] Guillain, G., Barre, J., Strohl, A., Sur un syndrome de radiculo-nevrite avec hyperalbuminose du liquide cephalorachidien sans reaction cellulaire. Remarques sur les caracteres cliniques et graphiques desrefl exes tendineux. Bull Mem Soc Med Hop Paris 28 (1916), 1462–1470.
37. [37] Eldar, A.H., Chapman, J., Guillain Barré syndrome and other immune mediated neuropathies: diagnosis and classification. Autoimmun Rev 13 (2014), 525–530.
38. [38] Korinthenberg, R., Schessl, J., Kirschner, J., Mönting, J.S., Intravenously administered immunoglobulin in the treatment of childhood Guillain–Barré syndrome: a randomized trial. Pediatrics 116 (2005), 8–14.
39. [39] Hughes, R.A., Swan, A.V., van Doorn, P.A., Intravenous immunoglobulin for Guillain–Barré syndrome. Cochrane Database Syst Rev, 9, 2014, CD002063.
40. [40] Anand, B., Nimisha, K., Guillain–Barré syndrome. Pharmacol Rep 62 (2010), 220–232.
41. [41] Hahn, A.F., Guillain–Barré syndrome. Lancet 352 (1998), 635–641.
42. [42] van den Berg, B., Fokke, C., Drenthen, J., van Doorn, P.A., Jacobs, B.C., Paraparetic Guillain–Barré syndrome. Neurology 82 (2014), 1984–1989.
43. [43] Yuki, N., Kokubun, N., Kuwabara, S., Sekiguchi, Y., Ito, M., Odaka, M., Hirata, K., Notturno, F., Uncini, A., Guillain–Barré syndrome associated with normal or exaggerated tendon reflexes. J Neurol 259 (2012), 1181–1190.
44. [44] Fokke, C., van den Berg, B., Drenthen, J., Walgaard, C., van Doorn, P.A., Jacobs, B.C., Diagnosis of Guillain–Barré syndrome and validation of Brighton criteria. Brain 137:Pt 1 (2014), 33–43.
45. [45] van Doorn, P.A., Ruts, L., Jacobs, B.C., Clinical features, pathogenesis, and treatment of Guillain–Barré syndrome. Lancet Neurol 7 (2008), 939–950.
46. [46] McKhann, G.M., Cornblath, D.R., Griffin, J.W., Ho, T.W., Li, C.Y., Jiang, Z., et al. Acute motor axonal neuropathy: a frequent cause of acute flaccid paralysis in China. Ann Neurol 33 (1993), 333–342.
47. [47] Griffin, J.W., Li, C.Y., Ho, T.W., Tian, M., Gao, C.Y., Xue, P., Mishu, B., Cornblath, D.R., Macko, C., McKhann, G.M., Asbury, A.K., Pathology of the motor–sensory axonal Guillain–Barré syndrome. Ann Neurol 39 (1996), 17–28.
48. [48] van den Berg, B., Walgaard, C., Drenthen, J., Fokke, C., Jacobs, B.C., van Doorn, P.A., Guillain–Barré syndrome: pathogenesis, diagnosis, treatment and prognosis. Nat Rev Neurol 10 (2014), 469–482.
49. [49] Roodbol, J., de Wit, M.C., Walgaard, C., de Hoog, M., Catsman-Berrevoets, C.E., Jacobs, B.C., Recognizing Guillain–Barré syndrome in preschool children. Neurology 76 (2011), 807–810.
50. [50] Al-Din, A.S., Jamil, A.S., Shakir, R., Coma and brain stem areflexia in brain stem encephalitis (Fisher's syndrome). Br Med J 291 (1985), 535–536.
51. [51] Roodbol, J., de Wit, M.C., Aarsen, F.K., Catsman-Berrevoets, C.E., Jacobs, B.C., Long-term outcome of Guillain–Barré syndrome in children. J Peripher Nerv Syst 19 (2014), 121–126.
52. [52] Hughes, R.A., Swan, A.V., Raphaël, J.C., Annane, D., van Koningsveld, R., van Doorn, P.A., Immunotherapy for Guillain–Barré syndrome: a systematic review. Brain 130 (2007), 2245–2257.
53. [53] Živković, S., Intravenous immunoglobulin in the treatment of neurologic disorders. Acta Neurol Scand, 2015 [Epub May 21].
54. [54] Darweesh, S.K., Polinder, S., Mulder, M.J., Baena, C.P., van Leeuwen, N., Franco, O.H., Jacobs, B.C., van Doorn, P.A., Health-related quality of life in Guillain–Barré syndrome patients: a systematic review. J Peripher Nerv Syst 19 (2014), 24–35.
55. [55] Ryan, M.M., Pediatric Guillain–Barré syndrome. Curr Opin Pediatr 25 (2013), 689–693.
56. [56] Wong, A.H., Umapathi, T., Nishimoto, Y., Wang, Y.Z., Chan, Y.C., Yuki, N., Cytoalbuminologic dissociation in Asian patients with Guillain–Barré and Miller Fisher syndromes. J Peripher Nerv Syst 20 (2015), 47–51.
57. [57] Agrawal, S., Peake, D., Whitehouse, W.P., Management of children with Guillain–Barré syndrome. Arch Dis Child Educ Pract Ed 92 (2007), 161–168.
58. [58] Walgaard, C., Lingsma, H.F., Ruts, L., Drenthen, J., van Koningsveld, R., Garssen, M.J., van Doorn, P.A., Steyerberg, E.W., Jacobs, B.C., Prediction of respiratory insufficiency in Guillain–Barré syndrome. Ann Neurol 67 (2010), 781–787.
59. [59] Ho, T.W., Mishu, B., Li, C.Y., Gao, C.Y., Cornblath, D.R., Griffin, J.W., Asbury, A.K., Blaser, M.J., McKhann, G.M., Guillain–Barré syndrome in northern China. Relationship to Campylobacter jejuni infection and anti-glycolipid antibodies. Brain 118 (1995), 597–605.
60. [60] Yikilmaz, A., Dogonay, S., Gumus, H., Per, H., Kumandas, S., Coskun, A., Magnetic resonance imaging of childhood Guillain–Barré syndrome. Childs Nerv Syst 26 (2010), 1103–1108.
61. [61] Zuccoli, G., Panigrahy, A., Bailey, A., Fitz, C., Redefining the Guillain–Barré spectrum in children: neuroimaging findings of cranial nerve involvement. Am J Neuroradiol 32 (2011), 639–642.
62. [62] Willison, H.J., Goodyear, C.S., Glycolipid antigens and autoantibodies in autoimmune neuropathies. Trends Immunol 34 (2013), 453–459.
63. [63] Liu, J., Wang, L.N., McNicol, E.D., Pharmacological treatment for pain in Guillain–Barré syndrome. Cochrane Database Syst Rev, 4, 2015, CD009950.
64. [64] Ruts, L., Drenthen, J., Jongen, J.L., Hop, W.C., Visser, G.H., Jacobs, B.C., van Doorn, P.A., Dutch GBS Study Group, Pain in Guillain–Barré syndrome: a long-term follow-up study. Neurology 75 (2010), 1439–1447.
65. [65] Vitaliti, G., Tabatabaie, O., Matin, N., Ledda, C., Pavone, P., Lubrano, R., Serra, A., Di Mauro, P., Cocuzza, S., Falsaperla, R., The usefulness of immunotherapy in pediatric neurodegenerative disorders: a systematic review of literature data. Hum Vaccin Immunother 11 (2015), 2749–2763.
66. [66] Pithadia, A.B., Kakadia, N., Guillain–Barré syndrome. Pharmacol Rep 62 (2010), 220–232.
67. [67] Schaller, B., Radziwill, A.J., Steck, A.J., Successful treatment of Guillain–Barré syndrome with combined administration of interferon-beta-1 and intravenous immunoglobulin. Eur Neurol 46 (2001), 167–168.
68. [68] Ostronoff, F., Perales, M.A., Stubblefield, M.D., Hsu, K.C., Rituximab-responsive Guillain–Barré syndrome following allogeneic hematopoietic SCT. Bone Marrow Transplant 42 (2008), 71–72.